Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital

Overview

Journal J Pers Med

Date 2021 Jun 2

PMID 34064668

Citations 8

Authors

Pritmohinder S Gill

Feliciano B Yu

Patricia A Porter-Gill

Bobby L Boyanton

Judy C Allen

Jason E Farrar

Aravindhan Veerapandiyan

Parthak Prodhan

Kevin J Bielamowicz

Elizabeth Sellars

Andrew Burrow

Joshua L Kennedy

Jeffery L Clothier

David L Becton

Don Rule

G Bradley Schaefer

Affiliations

Soon will be listed here.

Abstract

Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children's Hospital (ACH), a clinical PGx laboratory-based test was developed and implemented to provide guidance on 66 pediatric medications for genotype-guided dosing. This PGx test consists of 174 single nucleotide polymorphisms (SNPs) targeting 23 clinically actionable PGx genes or gene variants. Individual genotypes are processed to provide per-gene discrete results in star-allele and phenotype format. These results are then integrated into EPIC- EHR. Genomic indicators built into EPIC-EHR provide the source for clinical decision support (CDS) for clinicians, providing genotype-guided dosing.

Citing Articles

Genetically guided precision medicine clinical decision support tools: a systematic review.

Johnson D, Del Fiol G, Kawamoto K, Romagnoli K, Sanders N, Isaacson G J Am Med Inform Assoc. 2024; 31(5):1183-1194.

PMID: 38558013 PMC: 11031215. DOI: 10.1093/jamia/ocae033.

Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.

Tang Girdwood S, Hall M, Antoon J, Kyler K, Williams D, Shah S JAMA Netw Open. 2024; 7(2):e2355707.

PMID: 38349656 PMC: 10865156. DOI: 10.1001/jamanetworkopen.2023.55707.

Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics.

Watanabe H, Nagano N, Tsuji Y, Noto N, Ayusawa M, Morioka I Eur J Clin Pharmacol. 2023; 80(2):203-221.

PMID: 38078929 DOI: 10.1007/s00228-023-03598-x.

Translating Precision Health for Pediatrics: A Scoping Review.

Subasri M, Cressman C, Arje D, Schreyer L, Cooper E, Patel K Children (Basel). 2023; 10(5).

PMID: 37238445 PMC: 10217253. DOI: 10.3390/children10050897.

How to Implement a Pharmacogenetics Service at your Institution.

Cicali E, Lemke L, Al Alshaykh H, Nguyen K, Cavallari L, Wiisanen K J Am Coll Clin Pharm. 2023; 5(11):1161-1175.

PMID: 36589694 PMC: 9799247. DOI: 10.1002/jac5.1699.

References

Guy J, Patel I, Oestreich J . Clinical Application and Educational Training for Pharmacogenomics. Pharmacy (Basel). 2020; 8(3). PMC: 7558792. DOI: 10.3390/pharmacy8030163. View

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

Haga S . Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges. Pharmgenomics Pers Med. 2019; 12:273-285. PMC: 6800463. DOI: 10.2147/PGPM.S179172. View

Giacomini K, Yee S, Ratain M, Weinshilboum R, Kamatani N, Nakamura Y . Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012; 4(153):153ps18. PMC: 3963516. DOI: 10.1126/scitranslmed.3003471. View

Bielinski S, Olson J, Pathak J, Weinshilboum R, Wang L, Lyke K . Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014; 89(1):25-33. PMC: 3932754. DOI: 10.1016/j.mayocp.2013.10.021. View

Kongkaew C, Noyce P, Ashcroft D . Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42(7):1017-25. DOI: 10.1345/aph.1L037. View

Gregornik D, Salyakina D, Brown M, Roiko S, Ramos K . Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium. Pharmacogenomics J. 2020; 21(1):8-19. PMC: 7840501. DOI: 10.1038/s41397-020-00181-w. View

Cicali E, Wiisanen Weitzel K, Elsey A, Orlando F, Vinson M, Mosley S . Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. Genet Med. 2019; 21(10):2264-2274. PMC: 6768772. DOI: 10.1038/s41436-019-0500-7. View

Sunshine J, Meo N, Kassebaum N, Collison M, Mokdad A, Naghavi M . Association of Adverse Effects of Medical Treatment With Mortality in the United States: A Secondary Analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study. JAMA Netw Open. 2019; 2(1):e187041. PMC: 6484545. DOI: 10.1001/jamanetworkopen.2018.7041. View

10.

Dunnenberger H, Biszewski M, Bell G, Sereika A, May H, Johnson S . Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health Syst Pharm. 2016; 73(23):1956-1966. DOI: 10.2146/ajhp160072. View

11.

OKane D, Weinshilboum R, Moyer T . Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics. 2003; 4(1):1-4. DOI: 10.1517/phgs.4.1.1.22588. View

12.

Giri J, Moyer A, Bielinski S, Caraballo P . Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare. Pharmgenomics Pers Med. 2019; 12:305-318. PMC: 6826176. DOI: 10.2147/PGPM.S193185. View

13.

Hicks J, Sangkuhl K, Swen J, Ellingrod V, Muller D, Shimoda K . Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2016; 102(1):37-44. PMC: 5478479. DOI: 10.1002/cpt.597. View

14.

Serpe L, Calvo P, Muntoni E, DAntico S, Giaccone M, Avagnina A . Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics. 2009; 10(11):1753-65. DOI: 10.2217/pgs.09.103. View

15.

Van Driest S, McGregor T . Pharmacogenetics in clinical pediatrics: challenges and strategies. Per Med. 2013; 10(7). PMC: 3866691. DOI: 10.2217/pme.13.70. View

16.

Pirmohamed M . Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol. 2001; 52(4):345-7. PMC: 2014592. DOI: 10.1046/j.0306-5251.2001.01498.x. View

17.

Karnes J, Rettie A, Somogyi A, Huddart R, Fohner A, Formea C . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2020; 109(2):302-309. PMC: 7831382. DOI: 10.1002/cpt.2008. View

18.

Hines R . The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008; 118(2):250-67. DOI: 10.1016/j.pharmthera.2008.02.005. View

19.

de Wildt S, Tibboel D, Leeder J . Drug metabolism for the paediatrician. Arch Dis Child. 2014; 99(12):1137-42. DOI: 10.1136/archdischild-2013-305212. View

20.

Relling M, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui C, Stein C . Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2018; 105(5):1095-1105. PMC: 6576267. DOI: 10.1002/cpt.1304. View